n-3 PUFAs Reduce Mortality and Hospital Admissions in Patients With Symptomatic Hea...(ction (MI) inpost-myocardial infarction ...),Health

Date:9/2/2008

ction (MI) in post-myocardial infarction patients and for the treatment of hypertriglyceridaemia in the US, Europe, Middle East and Asia. This highly purified n-3 polyunsaturated fatty acid (n-3 PUFA) ethyl esters 90 is the first and only EU- and FDA-approved n-3 PUFAs-derived prescription drug.

Omacor(R) is not currently indicated for the treatment of symptomatic heart failure.

Further information about Omacor(R) can be found at http://www.Omacor.com

About Solvay Pharmaceuticals

Solvay Pharmaceuticals commercialises Omacor(R) (licensed-in from Pronova BioPharma) in 35 countries throughout Europe, Asia and the Middle East. Omacor(R) is the only Omega-3 product approved for secondary prevention in post-myocardial infarction patients and patients with hypertriglyceriademia. Omacor(R) contains the highly purified Omega-3 fatty acid (eicosapentaenoic and docosahexaenoic acids) ethyl esters 90 in a 1g capsule.

Solvay Pharmaceuticals is a research driven group of companies that constitutes the global pharmaceutical business of the Solvay Group. The company seeks to fulfil carefully selected, unmet medical needs in the therapeutic areas of neuroscience, cardiometabolic, influenza vaccines, gastroenterology and men's and women's health. Its 2007 sales were EUR2.6 billion, and it employs more than 9,000 people worldwide. For more information, visit http://www.solvaypharmaceuticals.com.

Solvay is an international chemical and pharmaceutical group with headquarters in Brussels. It employs more than 28,000 people in 50 countries. In 2007, its consolidated sales amounted to EUR9.6 billion, generated by its three sectors of activity: Chemicals, Plastics and Pharmaceuticals. Solvay (NYSE Euronext: SOLB.BE - Bloomberg: SOLB.BB - Reuters: SOLB.BR) is listed on the NYSE Euronext stock exchange in Brussels. Details are available a
'/>"/>

SOURCE Solvay Pharmaceuticals Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. Prasugrel Head-to-Head Study Showed Reduced Cardiovascular Events in Diabetes Patients by 30 Percent Compared with Clopidogrel
2. National Study Shows Magnesium Sulfate Reduces Risk of Cerebral Palsy in Premature Births
3. Bad News to Bad Bugs: Northern Antibiotics Develops Novel Polymyxins With Reduced Toxicity
4. DaVita Strives to Improve Quality of Life and Reduce Overall Costs of Kidney Care Through Community-Based Education
5. New Study: Pine Bark Significantly Reduces Menstrual Pain
6. ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies
7. Patients Taking Cymbalta(R) Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study
8. Video: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2 Diabetes
9. The Largest Ever Study of Diabetes Shows Intensive Glucose Control Reduces Serious Complications
10. CellCept(R) and a Reduced Level of CNI Shows Trend Towards Preservation of Kidney Function Versus a Standard-Dose CNI
11. Data Show Rufinamide, an Investigational Adjunctive Treatment for Lennox- Gastaut Syndrome, Reduced Drop Attacks by More Than 40%